FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality

The U.S. Food and Drug Administration today issued final guidance for manufacturers of cellular and gene therapy (CGT) products to implement a comprehensive, science- and risk-based plan for making sure their products meet potency standards.

ScopeUp collects Ontario and national pharmacy practice updates and links every item to its source. Verify details against the source document before changing workflows.